10-07-2020 | Commentary | Uitgave 7-8/2020 Open Access
The ‘president’s drug’
- Tijdschrift:
- Netherlands Heart Journal > Uitgave 7-8/2020
Tip
Swipe om te navigeren naar een ander artikel
Onze productaanbevelingen
1.
go back to reference Goodman JL, Borio L. Finding effective treatments for COVID-19. Scientific integrity and public confidence in a time of crisis. JAMA. 2020. https://doi.org/10.1001/jama.2020.6434. CrossRefPubMedPubMedCentral Goodman JL, Borio L. Finding effective treatments for COVID-19. Scientific integrity and public confidence in a time of crisis. JAMA. 2020.
https://doi.org/10.1001/jama.2020.6434.
CrossRefPubMedPubMedCentral
2.
3.
go back to reference Traebert M, et al. Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. Eur J Pharmacol. 2004;484:41–8. CrossRef Traebert M, et al. Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. Eur J Pharmacol. 2004;484:41–8.
CrossRef
4.
go back to reference Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers Y‑M. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf. 2018;41:919–31. CrossRef Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers Y‑M. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf. 2018;41:919–31.
CrossRef
5.
go back to reference White NJ. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis. 2007;7:549–58. CrossRef White NJ. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis. 2007;7:549–58.
CrossRef
6.
go back to reference Mzayek F, Deng H, Mather FJ, et al. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin Trials. 2007;2(1):e6. https://doi.org/10.1371/journal.pctr.0020006. CrossRefPubMedPubMedCentral Mzayek F, Deng H, Mather FJ, et al. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin Trials. 2007;2(1):e6.
https://doi.org/10.1371/journal.pctr.0020006.
CrossRefPubMedPubMedCentral
7.
go back to reference Lane JCE, Weaver J, Kostka K, et al. Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study. medRxiv. https://doi.org/10.1101/2020.04.08.20054551. Lane JCE, Weaver J, Kostka K, et al. Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study. medRxiv.
https://doi.org/10.1101/2020.04.08.20054551.
8.
go back to reference Gao J, Tian Z, Breakthrough YX. chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–3. 7. CrossRef Gao J, Tian Z, Breakthrough YX. chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–3. 7.
CrossRef
9.
go back to reference Gautret P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020. https://doi.org/10.1016/j.ijantimicag.2020.105949. CrossRefPubMedPubMedCentral Gautret P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020.
https://doi.org/10.1016/j.ijantimicag.2020.105949.
CrossRefPubMedPubMedCentral
10.
go back to reference Chen Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv;7: 2020.03.22.20040758. 2020. Chen Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv;7: 2020.03.22.20040758. 2020.
11.
go back to reference Rosenberg ES, Dulfort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020. https://doi.org/10.1001/jama.2020.8630. CrossRefPubMedPubMedCentral Rosenberg ES, Dulfort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020.
https://doi.org/10.1001/jama.2020.8630.
CrossRefPubMedPubMedCentral
12.
go back to reference Magagnoli J, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. MedRxiv. 2020; https://doi.org/10.1101/2020.04.16.20065920. CrossRefPubMedPubMedCentral Magagnoli J, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. MedRxiv. 2020;
https://doi.org/10.1101/2020.04.16.20065920.
CrossRefPubMedPubMedCentral
13.
go back to reference Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849. https://doi.org/10.1136/bmj.m1849. CrossRefPubMedPubMedCentral Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849.
https://doi.org/10.1136/bmj.m1849.
CrossRefPubMedPubMedCentral
14.
go back to reference Patil VM, Singhal S, Masand N. A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: efficacy, safety and clinical trials. Life Sci. 2020. https://doi.org/10.1016/j.lfs.2020.117775. CrossRefPubMedPubMedCentral Patil VM, Singhal S, Masand N. A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: efficacy, safety and clinical trials. Life Sci. 2020.
https://doi.org/10.1016/j.lfs.2020.117775.
CrossRefPubMedPubMedCentral
15.
go back to reference Van den Broek MPH, Möhlman JE, Abeln BGS, et al. Chloroquine-induced QTc prolongation in COVID-19 patients. Neth Heart J. 2020; https://doi.org/10.1007/s12471-020-01429-7. CrossRefPubMedPubMedCentral Van den Broek MPH, Möhlman JE, Abeln BGS, et al. Chloroquine-induced QTc prolongation in COVID-19 patients. Neth Heart J. 2020;
https://doi.org/10.1007/s12471-020-01429-7.
CrossRefPubMedPubMedCentral
16.
go back to reference Sinkeler FS, Berger FA, Muntinga HJ, Jansen MMPM. The risk for QTc interval prolongation in COVID-19 patients treated with chloroquine. Neth Heart J. 2020. https://doi.org/10.1007/s12471-020-01462-6 CrossRefPubMedPubMedCentral Sinkeler FS, Berger FA, Muntinga HJ, Jansen MMPM. The risk for QTc interval prolongation in COVID-19 patients treated with chloroquine. Neth Heart J. 2020.
https://doi.org/10.1007/s12471-020-01462-6
CrossRefPubMedPubMedCentral
17.
go back to reference Jankelson L, Karam G, Becker ML, Chinitz LA, Tsai M‑C. QT prolongation, torsades de pointes and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: a systematic review. Heart Rhythm. 2020; https://doi.org/10.1016/j.hrthm.2020.05.008. CrossRefPubMedPubMedCentral Jankelson L, Karam G, Becker ML, Chinitz LA, Tsai M‑C. QT prolongation, torsades de pointes and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: a systematic review. Heart Rhythm. 2020;
https://doi.org/10.1016/j.hrthm.2020.05.008.
CrossRefPubMedPubMedCentral
18.
go back to reference Szekely Y, Lichter Y, Shrkihe BA, Bruck H, Oster HS, Viskin S. Chloroquine-induced torsade de pointes in a COVID-19 patient. Heart Rhythm. 2020; https://doi.org/10.1016/j.hrthm.2020.04.046. CrossRefPubMedPubMedCentral Szekely Y, Lichter Y, Shrkihe BA, Bruck H, Oster HS, Viskin S. Chloroquine-induced torsade de pointes in a COVID-19 patient. Heart Rhythm. 2020;
https://doi.org/10.1016/j.hrthm.2020.04.046.
CrossRefPubMedPubMedCentral
19.
go back to reference Wu C‑I, Postema PG, Arbelo E, et al. SARS-CoV‑2, COVID-19 and inherited arrhythmia syndromes. Heart Rhythm. 2020; https://doi.org/10.1016/j.hrthm.2020.03.024. CrossRefPubMedPubMedCentral Wu C‑I, Postema PG, Arbelo E, et al. SARS-CoV‑2, COVID-19 and inherited arrhythmia syndromes. Heart Rhythm. 2020;
https://doi.org/10.1016/j.hrthm.2020.03.024.
CrossRefPubMedPubMedCentral
20.
go back to reference Lazzerini PE, Boutjdir M, Capecchi PL. COVID-19, arrhythmic risk and inflammation: mind the gap! Circulation. 2020; https://doi.org/10.1161/CIRCULATIONAHA.120.047293. CrossRefPubMed Lazzerini PE, Boutjdir M, Capecchi PL. COVID-19, arrhythmic risk and inflammation: mind the gap! Circulation. 2020;
https://doi.org/10.1161/CIRCULATIONAHA.120.047293.
CrossRefPubMed
21.
go back to reference Belardinelli L, Giles WR, Rajamani S, Karagueuzian HS, Shryock JC. Cardiac late Na(+) current: proarrhythmic effects, roles in long QT syndromes, and pathological relationship to CaMKII and oxidative stress. Heart Rhythm. 2015;12:440–8. CrossRef Belardinelli L, Giles WR, Rajamani S, Karagueuzian HS, Shryock JC. Cardiac late Na(+) current: proarrhythmic effects, roles in long QT syndromes, and pathological relationship to CaMKII and oxidative stress. Heart Rhythm. 2015;12:440–8.
CrossRef
22.
go back to reference Giudicessi JR, Roden DM, Wilde AAM, Ackerman MJ. Genetic susceptibility for COVID-19-associated sudden cardiac death in African Americans. Heart Rhythm. 2020; https://doi.org/10.1016/j.hrthm.2020.04.045. CrossRefPubMedPubMedCentral Giudicessi JR, Roden DM, Wilde AAM, Ackerman MJ. Genetic susceptibility for COVID-19-associated sudden cardiac death in African Americans. Heart Rhythm. 2020;
https://doi.org/10.1016/j.hrthm.2020.04.045.
CrossRefPubMedPubMedCentral
23.
go back to reference Gollob M. COVID-19, Clinical trials and QT-prolonging prophylactic therapy in healthy subjects: first, do no harm. J Am Coll Cardiol. 2020; https://doi.org/10.1016/j.jacc.2020.05.008. CrossRefPubMedPubMedCentral Gollob M. COVID-19, Clinical trials and QT-prolonging prophylactic therapy in healthy subjects: first, do no harm. J Am Coll Cardiol. 2020;
https://doi.org/10.1016/j.jacc.2020.05.008.
CrossRefPubMedPubMedCentral
- Titel
- The ‘president’s drug’
- Auteurs:
-
A. A. M. Wilde
J. A. Offerhaus
- Publicatiedatum
- 10-07-2020
- DOI
- https://doi.org/10.1007/s12471-020-01441-x
- Uitgeverij
- Bohn Stafleu van Loghum
- Tijdschrift
-
Netherlands Heart Journal
Uitgave 7-8/2020
Print ISSN: 1568-5888
Elektronisch ISSN: 1876-6250